Company news
Shanghai Shyndec Pharmaceutical Co., Ltd. news in 2025
Shanghai Shyndec Pharmaceutical Co., Ltd.'s news releases, calls and decks from 2025, newest first.
Announcement on Resolutions of the 1st Meeting of the 9th Board of Directors
December 24, 2025
Notice on Convening the 3rd Extraordinary General Meeting in 2025
December 8, 2025
Announcement on Election of Employee Director
November 21, 2025
Announcement on Attending Three-Quarter Report Collective Performance Briefing of Listed Companies in Shanghai Jurisdiction in 2025
November 5, 2025
Announcement on Progress in Public Listing and Transfer of Equity in a Holding Subsidiary and Completing Industrial and Commercial Change
October 31, 2025
Report for Q3 2025
October 29, 2025
Announcement on Prospective Winning of the 11th National Centralized Drug Procurement
October 28, 2025
Announcement on the Progress and Transaction Results of the Public Listing Transfer of Subsidiary Equity
October 17, 2025
Announcement on Wholly-owned Subsidiary Obtaining Approval for Marketing of Chemical APIs
October 10, 2025
Announcement on Resignation of Senior Management Members
October 9, 2025
Announcement on Resolutions of the 24th (Extraordinary) Meeting of the 8th Board of Directors
September 22, 2025
Announcement on the Voluntary Information Disclosure of Drug Passing the Consistency Evaluation for Generic Drugs
September 17, 2025
Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2025
September 15, 2025
Announcement on the Wholly-owned Subsidiary Obtaining the Approval Notice for Drug Supplementary Application
September 12, 2025
Announcement on Implementation of Semi-annual Dividend Distribution for 2025
September 8, 2025
Notice on Convening the 2nd Extraordinary General Meeting in 2025
August 29, 2025
Announcement on Progress in Public Listing and Transfer of Equity of Holding Subsidiary
August 28, 2025
Announcement on Resignation of Senior Management Member
August 3, 2025
Brief Announcement on Semi-annual Earnings for 2025
July 17, 2025
Announcement on Implementation of Dividend Distribution for 2024
July 9, 2025
Indicative Announcement on the Proposed Pre-Listing for Public Transfer of Equity Interests in a Controlling Subsidiary
June 30, 2025
Announcement on Wholly-owned Subsidiary Obtaining Notice of Approval for Marketing Application of Chemical APIs
June 27, 2025
Announcement on Resolutions of the 2024 Annual General Meeting
June 26, 2025
Announcement on the Voluntary Information Disclosure of the Holding Subsidiary's Drug Passing the Consistency Evaluation for Generic Drugs
June 20, 2025
Announcement on Progress in Accepting Drug Marketing Authorization by Holding Subsidiary
June 10, 2025
Announcement on Resolution of the 22nd Meeting of the 8th Board of Directors
June 5, 2025
Announcement on the Holding Subsidiary Obtaining the Approval Notice for Drug Supplementary Application
May 28, 2025
Announcement on Attending Collective Annual Report Performance Briefing of Listed Companies in Shanghai Jurisdiction in 2025
May 8, 2025
Report for Q1 2025
April 28, 2025